Dacomitinib (dacomitinib) dosage

Dacomitinib (Dacomitinib) is a targeted therapy used to treat patients with EGFR (epidermal growth factor receptor) mutation-positive non-small cell lung cancer (NSCLC). Dosage and usage are based on clinical trials and treatment experience.

The recommended initial dose of dacomitinib is 45 milligrams (mg) taken orally once daily. This dose is designed to effectively inhibit the growth and spread of EGFR mutation-positive tumors. Doctors will make dose adjustments based on the patient's specific condition and tolerance. For example, the initial dose may be adjusted in elderly patients or patients with specific health problems.

Dacomitinib is usually recommended to be taken after meals to reduce the occurrence of gastrointestinal discomfort and improve the absorption efficiency of the drug. Patients should avoid taking it at the same time with foods rich in metal ions such as calcium, magnesium, aluminum, iron, etc. These substances may affect the pharmacokinetics of Dacomitinib.

Dacomitinib is often used as part of long-term treatment to maintain disease control and prolong patient survival. During treatment, doctors will regularly evaluate the patient's condition and treatment effects to decide whether the dose needs to be adjusted or discontinued.

Dacomitinib may cause some common adverse reactions, such as skin reactions (such as rash, dryness, scaling), gastrointestinal problems (such as nausea, diarrhea), fatigue, etc. Doctors will provide appropriate symptomatic treatment measures, such as topical medications and anti-nausea medications, to reduce the severity and frequency of these adverse reactions.

Duringdacomitinibtreatment, patients require periodic clinical monitoring and evaluation. This includes regular imaging examinations (such as CT scans or PET-CT) and laboratory tests (such as blood tests and liver function tests) to promptly assess disease progression and treatment effects, while monitoring the occurrence and changes of adverse reactions.